Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis

Vista sencilla de ítem
dc.citation.journalTitleJournal of Evidence-Based Medicinespa
dc.contributor.authorCardona-Arias JA
dc.contributor.authorLópez-Carvajal L
dc.contributor.authorTamayo Plata MP
dc.contributor.authorDarío-Vélez I
dc.contributor.departmentDepartamento de Humanidades
dc.contributor.researchgroupEstudios de Filosofía, Hermenéutica y Narrativasspa
dc.date.accessioned2021-03-04T20:56:16Z
dc.date.available2021-03-04T20:56:16Z
dc.date.issued2017-05-30
dc.description.abstractObjective: The treatment of cutaneous leishmaniasis is toxic, has contraindications, and a high cost. The objective of this study was to estimate the cost-effectiveness of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. Methods: Effectiveness was the proportion of healing and safety with the adverse effects; these parameters were estimated from a controlled clinical trial and a meta-analysis. A standard costing was conducted. Average and incremental cost-effectiveness ratios were estimated. The uncertainty regarding effectiveness, safety, and costs was determined through sensitivity analyses. Results: The total costs were $66,807 with Glucantime and $14,079 with thermotherapy. The therapeutic effectiveness rates were 64.2% for thermotherapy and 85.1% for Glucantime. The average cost-effectiveness ratios ranged between $721 and $1275 for Glucantime and between $187 and $390 for thermotherapy. Based on the meta-analysis, thermotherapy may be a dominant strategy. Conclusion: The excellent cost-effectiveness ratio of thermotherapy shows the relevance of its inclusion in guidelines for the treatment. © 2017 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltdeng
dc.identifierhttps://eafit.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6642
dc.identifier.doi10.1111/jebm.12245
dc.identifier.issn17565383
dc.identifier.issn17565391
dc.identifier.otherPUBMED;28276641
dc.identifier.otherSCOPUS;2-s2.0-85019982051
dc.identifier.urihttp://hdl.handle.net/10784/26318
dc.languageeng
dc.language.isoengeng
dc.publisherBlackwell Publishing
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85019982051&doi=10.1111%2fjebm.12245&partnerID=40&md5=9b2968aa37cefaebd7cf731205e9cb77
dc.rightshttps://v2.sherpa.ac.uk/id/publication/issn/1756-5383
dc.sourceJournal of Evidence-Based Medicine
dc.subject.keywordantimony derivativeeng
dc.subject.keywordantiprotozoal agenteng
dc.subject.keywordmeglumine antimonateeng
dc.subject.keywordstibogluconate sodiumeng
dc.subject.keywordantiprotozoal agenteng
dc.subject.keywordArticleeng
dc.subject.keywordclinical effectivenesseng
dc.subject.keywordColombiaeng
dc.subject.keywordcontrolled clinical trial (topic)eng
dc.subject.keywordcost effectiveness analysiseng
dc.subject.keyworddrug costeng
dc.subject.keyworddrug efficacyeng
dc.subject.keyworddrug safetyeng
dc.subject.keywordhealingeng
dc.subject.keywordhealth care costeng
dc.subject.keywordhumaneng
dc.subject.keywordmajor clinical studyeng
dc.subject.keywordmeta analysis (topic)eng
dc.subject.keywordpatient safetyeng
dc.subject.keywordpriority journaleng
dc.subject.keywordsensitivity analysiseng
dc.subject.keywordskin leishmaniasiseng
dc.subject.keywordthermotherapyeng
dc.subject.keyworduncertaintyeng
dc.subject.keywordcost benefit analysiseng
dc.subject.keywordeconomicseng
dc.subject.keywordskin leishmaniasiseng
dc.subject.keywordthermotherapyeng
dc.subject.keywordAntiprotozoal Agentseng
dc.subject.keywordCost-Benefit Analysiseng
dc.subject.keywordDrug Costseng
dc.subject.keywordHumanseng
dc.subject.keywordHyperthermiaeng
dc.subject.keywordInducedeng
dc.subject.keywordLeishmaniasiseng
dc.subject.keywordCutaneouseng
dc.subject.keywordUncertaintyeng
dc.titleCost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasiseng
dc.typearticleeng
dc.typeinfo:eu-repo/semantics/articleeng
dc.typeinfo:eu-repo/semantics/publishedVersioneng
dc.typepublishedVersioneng
dc.type.localArtículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
J Evidence Based Medicine - 2017 - Cardona‐Arias - Cost‐effectiveness analysis of thermotherapy versus pentavalent.pdf
Tamaño:
275.29 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar

Colecciones

Artículos (EFHN)